ANEB Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	373.00
Średni wolumen	5 814.00
Kapitalizacja rynkowa	70.11M
EPS	$0 ( 2024-02-09 )
Następna data zysków	( $-0.110 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.59
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-29	Cundy Kenneth C	Buy	72 613	Stock Option (right to buy)
2024-02-29	Cundy Kenneth C	Buy	72 613	Stock Option (right to buy)
2023-12-18	English Aron R.	Buy	300 000	Common Stock
2023-11-13	English Aron R.	Buy	300 000	Common Stock
2023-12-18	English Aron R.	Sell	300 000	Common Stock

INSIDER POWER
65.41
Last 33 transactions
Buy: 5 891 747 \| Sell: 793 740

Anebulo Pharmaceuticals, Korelacja

10 Najbardziej pozytywne korelacje
NTGR	0.871
TCON	0.866
HMST	0.861
VYNT	0.855
RVLP	0.853
HONE	0.852
NTRS	0.849
MODV	0.849
SCOR	0.849
PEAR	0.848

10 Najbardziej negatywne korelacje
LIQT	-0.881
AVDL	-0.866
HSKA	-0.864
ISEE	-0.861
LABP	-0.86
BLU	-0.857
XLRN	-0.856
GXII	-0.855
NVSA	-0.854
HCTI	-0.852

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Anebulo Pharmaceuticals, Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-0.470

FY	2023
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-0.470

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-0.290

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.83

Financial Reports:

No articles found.

Anebulo Pharmaceuticals,

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.